COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,100 Articles (22,658 medRxiv, 8,442 bioRxiv)

Most recent first Previous |  Page 1573: Articles 15721-15730  | Next

County-Level Estimates of Excess Mortality associated with COVID-19 in the United States
Ackley, C., Lundberg, D. J., Elo, I. T., Preston, S. H., Stokes, A. C.
10.1101/2021.04.23.21255564 — Posted: 2021-04-25
Monitoring global trends in Covid-19 vaccination intention and confidence: a social media-based deep learning study
Zhou, X., de Figueiredo, A., Xu, Q., Lin, L., Kummervold, P. E., Larson, H., Jit, M., Hou, Z.
10.1101/2021.04.17.21255642 — Posted: 2021-04-25
Estimating the total morbidity burden of COVID-19
Smith, M. P.
10.1101/2021.04.20.21255818 — Posted: 2021-04-24 Discussion: Onsite
Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel
Goldberg, Y., Mandel, M., Woodbridge, Y., Fluss, R., Novikov, I., Yaari, R., Ziv, A., Freedman, L., Huppert, A.
10.1101/2021.04.20.21255670 — Posted: 2021-04-24 Discussion: Onsite
Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India
Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Das, S., Agarwal, A., Singh, S., Abraham, P., Panda, S., Mande, S., Swarup, R., Bhargava, B., Bhushan, R., NIC team, , INSACOG Consortium
10.1101/2021.04.22.440932 — Posted: 2021-04-24 Discussion: Onsite
Manufacturer Signal-to-Cutoff Threshold Underestimates Cumulative Incidence of SARS-CoV-2 Infection: Evidence from the Los Angeles Firefighters Study
Toubat, O., Berg, A. H., Sobhani, K., Mulligan, K., Hori, A. M., Bhattacharya, J., Sood, N.
10.1101/2021.04.20.21255829 — Posted: 2021-04-23
Analysis of the Number of Tests, the Positivity Rate, and Their Dependency Structure during COVID-19 Pandemic
Jamshidi, B., Bekrizadeh, H., Jamshidi Zargaran, S., Rezaei, M.
10.1101/2021.04.20.21255796 — Posted: 2021-04-23
Diagnostic accuracy of a novel SARS-CoV-2 antigen-detecting rapid diagnostic test from standardized self-collected anterior nasal swabs
Osmanodja, B., Budde, K., Zickler, D., Naik, M. G., Hofmann, J., Gertler, M., Hülso, C., Rössig, H., Horn, P., Seybold, J., Lunow, S., Bothmann, M., Barrera-Pesek, A., Mayrdorfer, M.
10.1101/2021.04.20.21255797 — Posted: 2021-04-23
Shut Down Schools, Knock Down the Virus? Causal Inference on the School Closures' Effect on the Spread of COVID-19
Fukumoto, K., McClean, C. T., Nakagawa, K.
10.1101/2021.04.21.21255832 — Posted: 2021-04-23
Frequency of neurological manifestations in COVID-19: a systematic review and meta-analysis of 350 studies
Misra, S., Kolappa, K., Prasad, M., Radhakrishnan, D., Thakur, K. T., Solomon, T., Michael, B. D., Winkler, A. S., Beghi, E., Guekht, A., Pardo, C. A. A., Wood, G. K., Chou, S. H.-Y., Fink, E. L., Schmutzhard, E., Kheradmand, A., Hoo, F. K., Kumar, A., Das, A., Srivastava, A. K., Agarwal, A., Dua, T., Prasad, K.
10.1101/2021.04.20.21255780 — Posted: 2021-04-23 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).